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Intratumoral Hypericin and KTP Laser
Therapy for Transplanted Squamous
Cell Carcinoma
Phil S. Chung, MD; Chung K. Rhee, MD; Kwang H. Kim, MD; Woo Paek, BA; Juliet Chung, BA;
Marcos B. Paiva, MD; Amir A. Eshraghi, MD; Dan J. Castro, MD; Romaine E. Saxton, PhD
Objectives/Hypothesis: To test intratumoral pho-
todynamic therapy (IPDT) as a new treatment for
squamous cell carcinoma in a preclinical tumor
model. Study Design and Methods: Human P3 squa-
mous carcinoma cells were transplanted subcutane-
ously in athymic nude mice and allowed to grow into
300- to 500-mm3 tumors. Hypericin dye at 1 mg/gm of
body weight was injected intratumorally (IT) or intra-
venously (IV). After 4 hours hypericin biodistribution
was assessed in ethanol extracts from tissues by fluo-
rescence spectroscopy. IPDT also was tested by KTP
laser fiberoptic insertion in tumors 4 hours after IT
dye injection compared to KTP532 laser therapy
alone (532 nm, 1W, 40–60 J, 0.6-mm fiber). Results:
Hypericin concentration in tissues was as follows: (IT
vs. IV) for tumors (3660 vs. 135 ng dye/gm tissue), lung
(760 vs. 6345), liver (75 vs. 935), blood (65 vs. 480) com-
pared to skin (465 vs. 110) or muscle (335 vs. 80) adja-
cent to the squamous cell tumors. Four hours after
dye injection, the tumor exhibited bright orange flu-
orescence when excited by KTP 532-nm green laser
light. The IPDT-treated tumors had a 3.32 6 0.32-mm
radius of cell destruction when H&E-stained sections
were examined compared with 2.5 6 0.38 mm for the
laser only control group (n 5 10, P 5 .003).
Conclusions: This pilot study indicates laser IPDT
with hypericin induces a significant increase in tu-
mor necrosis compared with laser alone and may be
useful as a less invasive adjuvant treatment for recur-
rent or inoperable human squamous cell cancers of
the head and neck. Key Words: Phototherapy, hyperi-
cin, interstitial laser fiberoptics, squamous cell
carcinoma.
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INTRODUCTION
Photodynamic therapy (PDT) is an adjunctive modal-
ity for treatment of cancer that is useful in ablation of
superficial malignancies. In PDT a light-activated photo-
sensitizer is administered, resulting in the production of
toxic oxygen species. Clinical use of PDT has been limited
by poor light penetration and low photosensitizer levels
within larger tumors. Laser thermal energy delivered by
imaging-guided fiberoptics is also being tested as a more
effective treatment for a number of inoperable cancers.
Palliation by interstitial laser therapy (ILT) is under eval-
uation as a useful alternative to surgical excision for the
ablation of metastatic breast and colon tumors as well as
advanced or recurrent squamous cell cancer of the head
and neck.1,2 One way to improve outcome in larger or
invasive tumors might be to combine ILT with PDT.
Among the most active new photosensitizers is hy-
pericin, a lipophilic dianthraquinone isolated from herbal
extracts of the plant St. John’s wort. Hypericin contains
extended pi-orbital electrons that are excited by ultravio-
let or visible light, leading to production of singlet oxygen
as well as protons and radical species, which results in
phototoxicity even under mildly hypoxic conditions.3 Con-
focal laser fluorescence microscopy has revealed initial
hypericin uptake in tumor cell membranes and mitochon-
dria with later migration into the nucleus.4 Several
groups have reported that photoactivation of hypericin at
nanomolar levels inhibits protein kinases, blocks growth
factors, and induces tumor cell apoptosis.5,6 Hypericin
photoexcitation also causes oxidative stress in mitochon-
dria and decreases ATP synthesis, leading to programmed
cell death.7
Human tumor transplants in nude mice have been
eliminated by phototherapy with 150 J/cm2 of white light
2 hours after intraperitoneal hypericin injection.8 Chung
et al.9 previously reported elevated hypericin uptake in
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tumors compared with adjacent normal tissues including
skin and muscle 4 hours after intravenous injection of dye
into human squamous cell carcinoma–bearing nude mice.
Recent clinical testing has revealed that hypericin was not
tumoricidal in a patient with mesothelioma exposed to
632-nm red laser light, but clear evidence of phototoxicity
was seen in two subjects after intradermal drug injection
when activated by green laser emissions at 514 nm rather
than by 632-nm or 670-nm red light.10,11
These preclinical and clinical in vivo studies with
hypericin in human tumors are encouraging but require
further exploration, especially in defining drug dose, route
of injection, and light delivery for optimal phototherapy
responses. Taken together, these initial hypericin experi-
ments suggest that improved tumor responses are likely if
careful selection of laser excitation wavelength is coupled
with optimal drug dose and route of injection. The current
study was performed after intralesional injection of the
dye in human tumor transplants in an attempt to increase
tumor sensitization and decrease normal tissue uptake as
well as to improve light delivery via intratumor laser
fiberoptics.
MATERIALS AND METHODS
Tumor Transplantation
UCLA-P3 human squamous cell carcinoma cultures were
grown in Costar T75 flasks, removed from monolayers with tryp-
sin, and counted. The P3 cell line was established in 1975 at
UCLA from a pulmonary squamous cell carcinoma of a 53-year-
old white male patient. The P3 cells were grown as monolayers in
a 5% CO2 incubator in RPMI 1640 media supplemented with 10%
fetal calf serum, L-glutamine, and antibiotics. These P3 cells (107
cells/0.1 mL) were injected subcutaneously into 6- to 8-week-old
BALB/c athymic nude mice and maintained in the UCLA Johnson
Cancer Center breeding colony. After 3 to 4 weeks, the squamous
cell carcinoma tumors reached volumes ranging from 300 to 500
mm3 when measured by vernier calipers. Volume was calculated
by the formula: V 5 p/6 (L 3 W 3 H). During therapy experi-
ments, the mice were housed in filter-top sterile cages under
subdued light and fed germ-free food and water. This human
tumor transplantation technique in nude mice and the experi-
mental protocols listed below received approval by the UCLA
Animal Research Committee following current National Insti-
tutes of Health guidelines.
Hypericin Biodistribution and Quantitative
Fluorescence
Hypericin was obtained from Roth (HPLC grade, Karlsruhe,
Germany). As shown in Figure 1, hypericin has a dianthraqui-
none structure that absorbs visible light at 545 nm and 590 nm
with fluorescence emission maximums at 595 nm and 640 nm.
Hypericin stock solutions at 2 mg/mL in 95% ethanol were diluted
immediately before use in normal saline. Hypericin (1 mg/g of
body weight) was injected transcutaneously into the tumor center
or intravenously via lateral tail vein using a 0.3-mL syringe with
a 30-G needle. Four hours after injection, mice were sacrificed
and tumors, blood, lung, liver, skin, and muscle were harvested.
Blood was obtained by cardiac puncture and sera were collected
after centrifugation. Skin and muscle were obtained from areas
adjacent to tumor. The specimens were weighed and stored in
airtight containers at 4°C until ethanol extraction and homoge-
nization were performed. Each specimen (100 mg) was diluted in
10 to 50 volumes of 95% ethanol and homogenized with a BioSpec
Tissue-Tearor (Bartlesville, OK), tubes were centrifuged for 5
minutes at 2400 rpm, and supernatants were stored in the dark.
Sera were diluted 20-fold with 95% ethanol before centrifugation
and supernatants were stored at 4°C in the dark before measure-
ment.
Fluorescence measurements were carried out in a spec-
trofluorometer (Fluoromax, Spex Industries, Edison, NJ) contain-
ing a 150-W xenon light source and a 1681 excitation monochro-
nometer driven by DM3000 computer software. The excitation
wavelength was selected at 588 nm, with the fluorescence emis-
sion maximum of 640 nm (Fig. 1) measured to quantify hypericin
in ethanol extracts. Fluorescence measurements were performed
on sample supernates with emission peak intensities recorded as
counts per second (CPS) and converted to ng dye/gm tissue using
1 to 1000 ng/mL hypericin in ethanol as calibration standards.
Adding known dye levels before homogenization showed that
extraction efficiency was more than 95% for most biopsied sam-
ples but less than 75% for skin specimens.
Interstitial Laser Therapy, Photodynamic
Therapy, and Histopathologic Evaluation
Five human squamous cell carcinoma control tumors in
nude mice were treated by ILT after ketamine/xylazine intraperi-
toneal anesthesia using a KTP laser (Laserscope, San Jose, CA.)
emitting continuous wave 532-nm green light. During laser op-
eration the 600-mm bare fiberoptic was inserted vertically
through the skin into each tumor and moved down to the tumor
base slowly over 40 to 60 seconds. The power setting of the KTP
laser was 1 W, with total energy delivery of 40 to 60 J adjusted in
proportion to 300 to 500 mm3 tumor size. Hypericin (20 mg/50 mL)
was injected directly into the heterotransplanted squamous cell
carcinoma tumors in nude mice (n 5 5). Four hours after intra-
tumor injection of hypericin, the entire tumor exhibited a bright
orange-colored fluorescence when excited by the KTP532 laser
and viewed through goggles to block the exciting green 532-nm
laser light. At this point the squamous cell carcinoma tumors
were treated by IPDT via laser fiberoptic insertion as described
above. Tumor specimens were harvested 48 hours after laser
treatment and fixed in formalin for at least 2 days. These speci-
mens were completely dehydrated in graded water alcohol mix-
tures and embedded in paraffin. The paraffin-embedded tumor
Fig. 1. Hypericin dianthraquinone structure and visible light excita-
tion/fluorescence spectra.
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specimens were sectioned parallel to the vertical fiberoptic inser-
tion axis before being stained with H&E. Sections of each speci-
men were examined by a light microscope to measure the extent
of tumor necrosis extending outward from the KTP laser bare
fiberoptic insertion track. The H&E-stained sections were viewed
at magnification 3 12 and three separate measurements were
performed to define a mean radius of necrosis for each tumor in
the ILT and IPDT groups (30 total measurements).
RESULTS
Biodistribution of Hypericin
The first experiment was to measure dye levels in
tumor and tissue extracts. Figure 2 compares the hyperi-
cin dye uptake seen 4 hours after intratumor versus in-
travenous injection. Hypericin injected intravenously in
squamous cell carcinoma–tumor bearing mice led to very
high dye levels at 4 hours in lungs (6350 ng/gm of tissue)
with elevated uptake in liver (935 ng/gm) and blood (480
ng/gm), whereas tumors (135 ng/gm), skin (110 ng/gm),
and muscle (80 ng/gm) had much lower concentrations. By
contrast, 4 hours after intratumor injection human squa-
mous cell tumor transplants retained the highest hyperi-
cin uptake (3660 ng/gm), as shown in Figure 2. Tissues
adjacent to tumor had clearly elevated dye levels, with
skin containing 465 ng/gm and muscle 335 ng/gm. This
dye uptake level was fivefold higher than in the same
tissues seen after intravenous injection. Lung uptake (760
ng/gm) was 15-fold reduced after intratumor injection
compared with intravenous injection, whereas liver (75
ng/gm) and blood (65 ng/gm) contained 10-fold lower dye
levels, as shown in Figure 2.
Histopathology of Tumor Response
A bright orange-colored fluorescence was observed in
the tumor center at the dye injection sites when excited by
green 532-nm light. This orange hypericin fluorescence
spread throughout the tumor with increased time after
dye injection but remained largely localized in the tumors
as shown in Figure 3. A noticeable increase in this fluo-
rescence intensity was observed soon after interstitial fi-
beroptic insertion and KTP laser illumination, suggesting
that IPDT induced immediate tumor cell membrane dam-
age and enhanced intracellular dye diffusion. Microscopic
examination of the KTP laser fiberoptic–induced lesions
in tumors by H&E staining after ILT or IPDT revealed a
central zone of tissue destruction and vaporization sur-
rounded by a zone of coagulative necrosis, in turn sur-
rounded peripherally by a zone of pallor as shown in
Figure 4. The ILT group (n 5 5) had a cell necrosis mean
distance of 2.5 6 0.38 mm from the laser fiber insertion
axis and the IPDT tumor group (n 5 5) had a 3.32
6 0.32-mm radius of cell destruction from the fiberoptic
axis. The difference was statistically significant (P 5 .003)
by unpaired t test, indicating that IPDT with hypericin led
to a measurable increase in tumor ablation.
DISCUSSION
Laser fiberoptic ablative surgery under the guidance
of magnetic resonance imaging or ultrasonography has
been tested as a less invasive alternative than conven-
tional surgical excision for tumor palliation in brain, pros-
tate, breast, liver, and head and neck malignancies. In
some cases ILT can be performed in the clinic under local
anesthesia and may be repeated at intervals to increase
the tumor response with less morbidity and cost than
conventional surgery.2 One way that may improve tumor
response is to inject light-sensitive anticancer drugs into
tumors before laser irradiation via fiberoptics.12 Vander-
werf et al.13 first reported strong phototoxicity of the KTP
laser and hypericin in human tumor cell lines.
In the current in vivo study hypericin was injected
directly into human squamous cell tumor transplants in
mice. The dye was activated by KTP532 laser light deliv-
ered via fiberoptics, leading to enhanced ablation and
intense orange-colored dye fluorescence throughout the
tumors. Gamache and Morgello14 have described his-
topathologic tissue changes induced by KTP laser fiberop-
tics including a central zone of tissue destruction and
vaporization surrounded by a zone of coagulative necrosis
enclosed in turn by an outer zone of pallor. Although the
wavelengths of the KTP532 laser and argon 514-nm laser
are similar, tissue interactions due to the KTP laser are
much less pigment dependent.14 Histopathologic observa-
Fig. 2. Hypericin biodistribution 4 hours after intratumor (IT) versus
intravenous (IV) injection.
Fig. 3. Laser-induced hypericin fluorescence in squamous cell
tumor 4 hours after intratumor injection.
Laryngoscope 110: August 2000 Chung et al.: Hypericin and KTP Laser Therapy
1314
tion of the specimens treated by IPDT in the present study
revealed that hypericin-sensitized tumors contained a sig-
nificantly wider area of cellular destruction than after ILT
alone.
Vandenbogaerde et al.8 previously reported that hy-
pericin uptake and fluorescence were enhanced in tumors
after light exposure, suggesting that increased tumor per-
meability may have been induced by PDT. Interestingly,
in the current study an increase in hypericin fluorescence
intensity also was seen when the tumor was illuminated
by KTP laser light. A 4-hour interval between intratumor
dye injection and KTP laser therapy led to visible hyperi-
cin uptake, with orange fluorescence rapidly diffusing
throughout the transplanted squamous cell tumors. This
intralesional injection resulted in 25-fold higher tumor
retention of hypericin at 4 hours compared with systemic
injection and 10-fold less dye in lungs, but there were in-
creased dye levels in skin and muscle adjacent to tumors.
Clearly visible dye diffusion in tumors is likely to be
a major advantage for surgeons before and during laser
IPDT. Even at 4 hours after injection, minimal hypericin
fluorescence was detected beyond the squamous cell car-
cinoma tumor margins. This observation indicates that
intratumor dye injection may provide real advantages for
both tumor localization and decreased normal tissue pho-
totoxicity compared with conventional systemic dye ad-
ministration. Intratumor KTP532 laser fiberoptic delivery
of green light with limited penetration capability into
adjacent tissues also allows precise surgical control to
monitor intraoperative fluorescence and avoid normal tis-
sue phototoxicity. Cylindrical diffusers have been reported
to increase both treatment volume and lateral light dis-
tribution by laser fiberoptics for tumor therapy.15 The
recent development of diode and fiberoptic lasers allows
use of deeply penetrating near infrared light with photo-
sensitizers. One or more of these approaches may lead to
a more effective phototherapy for patients with head and
neck cancer.
CONCLUSION
A new approach for photodynamic therapy was tested
using direct intralesional injection of hypericin before in-
terstitial KTP532 laser fiberoptic insertion and illumina-
tion of human squamous cell tumors transplanted in athy-
mic nude mice. Hypericin dye fluorescence was visible via
laser illumination immediately after injection and rapidly
diffused to the margins of the squamous cell carcinoma
tumors. A much higher concentration of hypericin was
retained in the tumors 4 hours after intralesional dye
administration compared with intravenous dye adminis-
tration. Significant photoactivation of hypericin by the
KTP laser fiber resulted in an increased radius of tissue
destruction in tumors treated by IPDT versus ILT when
compared by histopathology. This intratumor photother-
apy method must be tested further before optimal drug
dose, route, timing, and laser dosimetry can be defined for
clinical evaluation as an adjuvant therapy in head and
neck cancer patients.
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